AstraZeneca PLC
LSE:AZN
AstraZeneca PLC
LSE:AZN
Price:
12 050 GBX
-0.87%
Updated:
May 6, 2024
AstraZeneca PLC
Research & Development
|
AstraZeneca PLC
Research & Development Peer Comparison
Comparables:
GSK
VRNA
INDV
HIK
DPH
Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
AstraZeneca PLC
LSE:AZN
|
Research & Development
-$10.3B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-9%
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Research & Development
-£5.8B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-5%
|
|
|
Verona Pharma PLC
NASDAQ:VRNA
|
Research & Development
-$17.2m
|
CAGR 3-Years
27%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Indivior PLC
LSE:INDV
|
Research & Development
-$106m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Research & Development
-$149m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-14%
|
|
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Research & Development
-£57.5m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-22%
|
See Also
What is AstraZeneca PLC's Research & Development?
Research & Development
-10.3B
USD
-10.3B
USD
Based on the financial report for Dec 31, 2023, AstraZeneca PLC's Research & Development amounts to -10.3B USD.
What is AstraZeneca PLC's Research & Development growth rate?
Research & Development CAGR 10Y
-9%
-9%
Over the last year, the Research & Development growth was -7%. The average annual Research & Development growth rates for AstraZeneca PLC have been -19% over the past three years , -14% over the past five years , and -9% over the past ten years .
You don't have any saved screeners yet
